The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Researchers have unveiled a novel approach to tackle obesity by targeting fat absorption in the small intestine. The ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

Hoping your company will begin paying for anti-obesity medications like Wegovy? You may be in luck. A growing number of employers are considering covering the blockbuster weight-loss drugs ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related diseases, new research has concluded.

When you think of brain stimulating medtech, startups building wearables as therapeutics probably aren't the first thing that ...